Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was grante...
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)
- First Posted Date
- 2014-04-09
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 310
- Registration Number
- NCT02108652
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Jacksonville, Florida, United States
🇺🇸Stanford Cancer Center, Stanford, California, United States
🇺🇸Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 673
- Registration Number
- NCT02091141
- Locations
- 🇺🇸
University Of Chicago Medical Center; Section Of Hematology/Oncology, Chicago, Illinois, United States
🇺🇸MD Anderson, Houston, Texas, United States
🇺🇸University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2020-01-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 667
- Registration Number
- NCT02031458
- Locations
- 🇺🇸
Angeles Clinic & Rsch Inst, Los Angeles, California, United States
🇺🇸Emory Uni - Winship Cancer Center; Hematology/Oncology, Atlanta, Georgia, United States
🇺🇸The Cleveland Clinic Foundation, Cleveland, Ohio, United States
A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT02013219
- Locations
- 🇺🇸
Yale University School Of Medicine, New Haven, Connecticut, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇭🇰The Chinese University of Hong Kong, Shatin, Hong Kong
A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy
- Conditions
- Interventions
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2019-12-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1225
- Registration Number
- NCT02008227
- Locations
- 🇺🇸
Comprehensive Blood/Cancer Ctr, Bakersfield, California, United States
🇺🇸Roy & Patricia Disney Family Cancer Center, Burbank, California, United States
🇺🇸St. Jude Heritage Healthcare; Virgiia K.Crosson Can Ctr, Fullerton, California, United States
Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2013-11-20
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 153
- Registration Number
- NCT01988896
- Locations
- 🇺🇸
Massachusets General Hospital Clinical Trial Network and Institute, Boston, Massachusetts, United States
🇺🇸Compass Oncology, Portland, Oregon, United States
🇺🇸Texas Oncology, P.A., Arlington, Texas, United States
A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR"
- First Posted Date
- 2013-07-19
- Last Posted Date
- 2019-10-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 287
- Registration Number
- NCT01903993
- Locations
- 🇺🇸
Kaiser Permanente - Vallejo, Vallejo, California, United States
🇺🇸New York Oncology Hematology, P.C., Albany, New York, United States
🇺🇸Wenatchee Valley Hospital & Clinics, Wenatchee, Washington, United States
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
- Conditions
- Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Oropharyngeal p16INK4a-Negative Squamous Cell CarcinomaStage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7
- Interventions
- Drug: AtezolizumabProcedure: BiopsyBiological: CetuximabProcedure: Biospecimen CollectionDrug: CisplatinProcedure: Computed TomographyDrug: DocetaxelRadiation: Intensity-Modulated Radiation TherapyOther: Laboratory Biomarker AnalysisProcedure: Magnetic Resonance ImagingOther: Quality-of-Life Assessment
- First Posted Date
- 2013-03-14
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 613
- Registration Number
- NCT01810913
- Locations
- 🇺🇸
Cleveland Clinic Akron General, Akron, Ohio, United States
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸The Kirklin Clinic at Acton Road, Birmingham, Alabama, United States
A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2012-08-03
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT01656642
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸The Angeles Clinic and Research Institute - W LA Office, Los Angeles, California, United States
A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2012-07-06
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT01633970
- Locations
- 🇺🇸
Uni of Chicago, Chicago, Illinois, United States
🇺🇸Carolina BioOncology Institute; Can Therapy & Res Ctr, Huntersville, North Carolina, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.